Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377874 | 1.00 | MAPT (0.46) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL1484906 | 0.98 | MAPT (0.44) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL29378036 | 0.98 | MAPT (0.44) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL2068884 | 0.95 | MAPT (0.41) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL3606878 | 0.88 | HTR3A (0.39) | MAPTALDH1A1LMNAALOX12NPSR1 | |
| SCHEMBL578540 | 0.87 | HTR3A (0.42) | ALDH1A1SMN1; SMN2DGAT1LPLLIPG | |
| SCHEMBL31212828 | 0.87 | ALDH1A1 (0.49) | MAPTALDH1A1LMNACNR2SMN1; SMN2 | |
| SCHEMBL29542633 | 0.87 | HTR3A (0.42) | ALDH1A1SMN1; SMN2DGAT1LPLLIPG | |
| SCHEMBL142528 | 0.87 | ALDH1A1 (0.49) | MAPTALDH1A1LMNACNR2SMN1; SMN2 | |
| SCHEMBL23611656 | 0.86 | KMT2A (0.41) | MAPTALDH1A1LMNACNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4602046-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | Masarykova Univerzita (CZ) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025067168-A1 | AZA FUSED RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2025-02-20 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| EP-4464701-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Dong Wha Pharm. Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| WO-2012085474-A1 | PROCESS FOR PREPARING CHIRAL AMINO ACIDS | DIVERCHIM (FR) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011145035-A1 | NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | INDIAN INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2011-11-17 | — | — | US | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| EP-2300465-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | Astex Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008088881-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | MAPT 2485/4885ALDH1A1 4773/4885LMNA 1301/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | MAPT 890/4885ALDH1A1 3885/4885LMNA 3740/4885 |
| US-20250059180-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CYP2C9, CYP1B1, SULT1A1 | MAPT 1433/4885ALDH1A1 111/4885LMNA 4061/4885 |
| US-20110281865-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES | MAP4K2, MAP4K3, MAP3K1 | MAPT 2960/4885ALDH1A1 3373/4885LMNA 2312/4885 |
| US-20100256097-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | MAPT 4023/4885ALDH1A1 3244/4885LMNA 4183/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | MAPT 341/4885ALDH1A1 2781/4885LMNA 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.